Professor Robert MacLaren (Vice-Chancellor's Innovation Award Overall Winner & Winner of Inspiring Leader Category) discusses Gene therapy for blindness.
Gene therapy may help to slow or even stop the degeneration in genetic eye diseases. Research led by Professor Robert MacLaren led to the spinout of Nightstar which was acquired by Biogen for $877 million in early 2019 – just five years after its founding. The deal ranks as the third most valuable British biotech exit in the last two decades and the technology has huge therapeutic potential.
https://www.ox.ac.uk/research/innovation-conversations
Gene therapy may help to slow or even stop the degeneration in genetic eye diseases. Research led by Professor Robert MacLaren led to the spinout of Nightstar which was acquired by Biogen for $877 million in early 2019 – just five years after its founding. The deal ranks as the third most valuable British biotech exit in the last two decades and the technology has huge therapeutic potential.
https://www.ox.ac.uk/research/innovation-conversations
- Category
- Academic
Sign in or sign up to post comments.
Be the first to comment